Major adverse cardiovascular events in the Psoriasis Longitudinal Assessment and Registry Study (PSOLAR): Current status of observations - 09/05/15
Alice B. Gottlieb, MD, PhD, Tufts Medical Center, Boston, MA, United States; Robert Bissonnette, MD, Innovaderm Research, Inc, Montreal, Quebec, Canada; Francisco Kerdel, MD, Florida Academic Dermatology Centers, Miami, FL, United States; Luigi Naldi, MD, Centro Studi GISED, Ospedali Riuniti, Bergamo, Italy; Kim Papp, MD, PhD, K. Papp Clinical Research and Probity Research, Waterloo, Ontario, Canada; Kavitha Goyal, MD, Janssen Scientific Affairs, LLC, Horsham, PA, United States; Steve Calabro, MS, MBA, Janssen Scientific Affairs, LLC, Horsham, PA, United States; Wayne Langholff, PhD, Janssen Scientific Affairs, LLC, Horsham, PA, United States; Steve Fakharzadeh, MD, Janssen Scientific Affairs, LLC, Horsham, PA, United States
Le texte complet de cet article est disponible en PDF.| 100% is Sponsored by Janssen Scientific Affairs, LLC. |
Vol 72 - N° 5S1
P. AB240 - mai 2015 Retour au numéro
Article précédent
- Maintenance of clinical response with long-term brodalumab (AMG 827) therapy for psoriasis: Week 144 results from an open-label extension study
- Malignancies in the psoriasis longitudinal assessment and registry (PSOLAR) study: Current status of observations
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?